drugset / Trial / NCT00440518

A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis

NCT00440518

Phase 2 Completed 218 enrolled UCB Pharma
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.

Timeline

Start
2007-02
Primary completion
2008-07
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lacosamide Other / unclassified 100 mg Oral
Subject Lacosamide Other / unclassified 300 mg Oral

Indications